Live Breaking News & Updates on Anthony Rothe Memorial

 E-Mail
Research led by scientists at Children s Cancer Institute and published this week in the international journal,
Clinical Cancer Research, has found a combination of therapies that appears to be highly effective against high-risk neuroblastoma and other forms of aggressive childhood cancer.
Up to half of all cases of neuroblastoma newly diagnosed in children are high-risk , meaning the cancer grows aggressively and is difficult to treat. Despite receiving intensive treatment, most children with high-risk disease die within five years of diagnosis, while those who survive are often left with serious long-term health effects.
Professor Michelle Haber AM, a senior author on the paper and co-head of the Molecular Targets and Cancer Therapeutics theme at Children s Cancer Institute, said children diagnosed with high-risk neuroblastoma have less than a 50-50 chance of survival. That is a devastating prognosis. We are absolutely determined to find better way ....

New South Wales , Lin Xiao , Tania Ewing , National Health , Kids Cancer Alliance , Cancer Institute , Tenix Foundation , Cancer Council , Stanford Brown Inc Sydney , Experimental Therapeutics Group , Goodridge Foundation , Children Cancer Institute , Research Council , Clinical Cancer Research , Anthony Rothe Memorial , Molecular Targets , Cancer Therapeutics , Research Officer , Neuroblastoma Australia , Anthony Rothe Memorial Trust , Medical Research Council , Stanford Brown , புதியது தெற்கு வேல்ஸ் , லின் கிஷியஓ , டானியா ய்விஂக் , தேசிய ஆரோக்கியம் ,